Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ciprofloxacin for gyrA serine 91 genotype Neisseria gonorrhoeae
NCT02961751Completed
- Sponsor
- National Institute of Allergy and Infectious Diseases
- Start
- Oct 2016
- Primary completion
- Jan 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Open-label, single-arm trial of ciprofloxacin in gonorrhea, sponsored by National Institute of Allergy and Infectious Diseases. Primary endpoint: Percentage of Subjects Infected With Gyrase A (gyrA) Serine 91 Genotype of Neisseria Gonorrhoeae With Microbiological Cure. Started Oct 2016; status: completed.
02
Drugs
ciprofloxacin
03
Conditions
gonorrhea
Beyond the preview
Go deeper on NCT02961751.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02961751.